Future therapies for inflammatory bowel disease

Current Gastroenterology Reports

Volumn 5, Issue 6, 2003, Pages 518-523

  Bickston, Stephen J ^a   Comerford, Lawrence W ^a   Cominelli, Fabio ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIBIOTIC AGENT; BUDESONIDE; CHIMERIC ANTIBODY; CORTICOSTEROID; CYTOKINE; FISH OIL; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 4; LINSEED OIL; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MICROSPHERE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREBIOTIC AGENT; PROBIOTIC AGENT; RECOMBINANT EPIDERMAL GROWTH FACTOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TACROLIMUS; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; ALLOTRAP; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONSTIPATION; CROHN DISEASE; DELAYED RELEASE FORMULATION; DIET SUPPLEMENTATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; ENTERIC FEEDING; ENTERITIS; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; NONHUMAN; NUTRITIONAL SUPPORT; REVIEW; ULCERATIVE COLITIS; VIRAL GENE THERAPY; ANIMAL; ANIMAL MODEL; GENE THERAPY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LACTOBACILLUS;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOBACILLUS; MODELS, ANIMAL; PEPTIDES; PROBIOTICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542540146     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0043-5     Document Type: Review

References (48)

1. Pizarro TT, Arseneau KO, Cominelli F: Lessons from genetically engineered animal models XI. Novel mouse models to study pathogenic mechanisms of Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2000, 278:G665-6699.
2. Rutgeerts P, Geboes K, Peeters M, et al.: Effect of fecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991, 338:771-774.
3. D'Haens G, Geboes K, Peeters M, et al.: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262-267.
4. Fasoli R, Kettlewell MG, Mortensen N, Jewell DP: Response to faecal challenge in defunctioned colonic Crohn's disease: prediction of long-term course. Br J Surg 1990, 77:616-617.
5. Hiwatashi N: Enteral nutrition for Crohn's disease in Japan. Dis Colon Rectum 1997, 40:S48-S53.
6. Belluzzi A, Brignola C, Campieri M, et al.: Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996, 334:1557-1560.
7. Sartor RB: The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol 1997, 148:567-576.
8. Swidsinski A, Ladhoff A, Pernthaler A, et al.: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122:44-54.
9. Guarner F, Schaafsma GJ: Probiotics. Int J Food Microbiol 1998, 39:237-238.
10. Madsen K, Cornish A, Soper P, et al.: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580-591.
11. Neish AS, Gewirtz AT, Zeng H, et al.: Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000, 289:1560-1563.
12. Rembacken BJ, Snelling AM, Hawkey PM, et al.: Non-pathogenic Escherichia coli versus mesalamine for the treatment of ulcerative colitis: a randomized trial. Lancet 1999, 354:635-639.
13. Kruis W, Schutz E, Fric P, et al.: Double-blind comparison of an oral Escherichia coli preparation and mesalamine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 11:853-858.
14. Wallet F, Dessein R, Armand S, Courcol RJ: Molecular diagnosis of endocarditis due to Lactobacillus casei subsp. rhamnosus. Clin Infect Dis. 2002, 35:117-119.
15. Lherm T, Monet C, Nougiere B, et al.: Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002, 28:797-801.
16. Venturi A, Gionchetti P, Rizzello F, et al.: Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999, 13:1103-1108.
17. Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
18. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
19. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000, 45:1462-1464.
20. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
21. Targan SR, Hanauer SB, van Deventer SJH, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997, 337:1029-1035.
22. Hanaeur SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002, 359:1541-1549.
23. Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
24. Sands B, van Deventer S, Bernstein C, et al.: Long-term treatment of fistulizing Crohn's disease: response to infliximab in the ACCENT II trial through 54 weeks [abstract]. Gastroenterology 2002, 122:A81.
25. Sandborn WJ, Targan SR: Biologic therapy of inflammatory bowel diseases. Gastroenterology 2002, 122:1592-1608.
26. Lugering A, Schmidt M, Lugering N, et al.: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
27. Marini M, Bamias G, Rivera-Nieves J, et al.: TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci U S A 2003, 100:8366-8371.
28. Neurath MF, Fuss I, Kelsall BL, et al.: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995, 182:1281-1290.
29. Salmi M, Alanen K, Grenman S, et al.: Immune cell trafficking in utero and during early life is dominated by the mucosal addressin MAdCAM-1 in humans. Gastroenterology 2001, 121:853-864.
30. Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn's disease. N Engl J Med 2003, 348:24-32.
31. Pizarro TF, Michie MH, Bentz M, et al.: IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999, 162: 6829-6835.
32. Cordoba-Rodriguez R, Frucht DM: IL-23 and IL-27: new members of the growing family of IL-12-related cytokines with important implications for therapeutics. Expert Opin Biol Ther. 2003, 3:715-723.
33. Elson CO, Beagley KW, Sharmanov AT, et al.: Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 1996, 157:2174-2185.
34. Bar-Meir S, Chowers Y, Lavy A, et al.: Budesonide versus prednisone in the treatment of active Crohn's disease: the Israeli Budesonide Study Group. Gastroenterology 1998, 115:835-840.
35. Bickston SJ, Cominelli F: Recombinant interleukin 10 for the treatment of active Crohn's disease: lessons in biologic therapy. Gastroenterology 2000, 119:1781-1783.
36. Sinha A, Nightingale J, West KP, et al.: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003, 349:350-357.
37. Iyer S, Lahana R, Buelow R: Rational design and development of RDP58. Curr Pharm Des 2002, 8:2217-2229.
38. Steidler L, Hans W, Schotte L, et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
39. Nakase H, Okazaki K, Tabata Y, Chiba T: Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. J Gastroenterol 2003, 38:59-62.
40. Lamprecht A, Ubrich N, Yamamoto H, et al.: Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001, 299:775-781.
41. Bonen DK, Cho JH: The genetics of inflammatory bowel disease. Gastroenterology 2003, 124:521-536.
42. Binder V: Genetic epidemiology in inflammatory bowel disease. Dig Dis 1998, 16:351-355.
43. Sands BE: Crohn's disease. In Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Edited by Feldman M, Friedman LS, Sleisenger MH. Philadelphia: WB Saunders; 2002:2005-2038.
44. Hendrickson BA, Gokhale R, Cho JH: Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002, 15:79-94.
45. Kyo K, Parkes M, Takei Y, et al.: Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet 1999, 8:307-311.
46. Katayama K, Wada K, Nakajima A, et al.: A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003, 124:1538-1542.
47. Sasaki M, Jordan P, Houghton J, et al.: Transfection of IL-10 expression vectors into endothelial cultures attenuates alpha4beta7-dependent lymphocyte adhesion mediated by MAdCAM-1. BMC Gastroenterology 2003, 3:3.
48. Macdonald TT: Viral vectors expressing imunoregulatory cytokines to treat inflammatory bowel disease. Gut 1998, 42:460-461.